{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:30:03Z","timestamp":1760189403273,"version":"3.37.3"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T00:00:00Z","timestamp":1416182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Some patients with \u03b2 thalassaemia experience non\u2010progressive creatinine increases with deferasirox, mostly within normal limits; the mechanisms involved are not fully elucidated. The effects of deferasirox on renal haemodynamics, including glomerular filtration rate (<jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content>) and renal plasma flow (<jats:styled-content style=\"fixed-case\">RPF<\/jats:styled-content>), were investigated in a Phase I, open\u2010label study in \u03b2 thalassaemia major patients with iron overload. Patients received deferasirox 30\u00a0mg\/kg\/d up to Week 8, followed by a 2\u2010week washout period, and extended treatment up to Week 104 with a 4\u2010week washout period. In the short\u2010term study (<jats:italic>n<\/jats:italic>\u00a0=\u00a011), mean <jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">RPF<\/jats:styled-content> declined from baseline to Week 8 (mean [%] change:\u22129\u00b72 [\u22129\u00b75%] and \u2212105\u00b77\u00a0ml\/min [\u221217\u00b78%], respectively). A similar pattern was observed during the long\u2010term study (<jats:italic>n<\/jats:italic>\u00a0=\u00a05); mean <jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">RPF<\/jats:styled-content> decreased up to Week 52 (\u221219\u00b71 [\u221217\u00b77%] and \u2212155\u00b76\u00a0ml\/min [\u221226\u00b71%]), with similar change at Week 104 (\u221218\u00b74 [\u221217\u00b72%] and \u2212115\u00b79\u00a0ml\/min [\u221219\u00b76%]). Measures returned to baseline values after each washout. Serum creatinine and creatinine clearance followed a similar pattern. Effects of deferasirox on renal haemodynamics were mild and reversible for up to 2\u00a0years of treatment, with no progressive worsening of renal function over time. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>: <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00560820.<\/jats:p>","DOI":"10.1111\/bjh.13217","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T12:20:12Z","timestamp":1416226812000},"page":"882-890","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Deferasirox effect on renal haemodynamic parameters in patients with transfusion\u2010dependent \u03b2 thalassaemia"],"prefix":"10.1111","volume":"168","author":[{"given":"Antonio","family":"Piga","sequence":"first","affiliation":[{"name":"Universit\u00e0 di Torino Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Fracchia","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Torino Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Lai","sequence":"additional","affiliation":[{"name":"Ospedale Regionale Microcitemie Cagliari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[{"name":"Ca Granda Foundation IRCCS Universit\u00e0 di Milano Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimund","family":"Hirschberg","sequence":"additional","affiliation":[{"name":"LABioMed\/Harbor\u2010UCLA Medical Center Torrance CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Wegener","sequence":"additional","affiliation":[{"name":"Novartis Pharma SAS Rueil Malmaison France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Bouillaud","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Luca","family":"Forni","sequence":"additional","affiliation":[{"name":"Ospedale Galliera Genoa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01819.x"},{"key":"e_1_2_8_3_1","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna\u2010Pignatti C.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014696"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-316646"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000287238"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnm.0000136715.71820.4a"},{"key":"e_1_2_8_10_1","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once\u2010daily oral chelating agent, in pediatric patients with \u03b2\u2010thalassemia major","volume":"91","author":"Galanello R.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.69.4.289"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1824-7288-36-39"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1179\/102453311X12953015767662"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2003.00507.x"},{"key":"e_1_2_8_15_1","first-page":"371","article-title":"The effects of subcutaneous deferoxamine administration on renal function in thalassemia major","volume":"54","author":"Koren G.","year":"1991","journal-title":"International Journal of Hematology"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00740110"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-0753-x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111070"},{"key":"e_1_2_8_19_1","first-page":"147","article-title":"Measurement of effective renal plasma flow (ERPF) with 123I\u2010orthoiodohippurate (I\u2010123\u2010OIH)","volume":"14","author":"Nakashima R.","year":"1996","journal-title":"Radiation Medicine"},{"key":"e_1_2_8_20_1","unstructured":"Novartis Pharmaceuticals. (2013)EXJADE\u00ae(deferasirox) US Prescribing Information. Available at:http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/exjade.pdf."},{"key":"e_1_2_8_21_1","unstructured":"Novartis Pharmaceuticals UK Ltd. (2014)Summary of Product Characteristics \u2010 EXJADE 125\u00a0mg 250\u00a0mg 500\u00a0mg dispersible tablets. Available at:http:\/\/www.medicines.org.uk\/emc\/medicine\/18805\/."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217455"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.049957"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2010.08.004"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00985.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1588-x"},{"key":"e_1_2_8_27_1","first-page":"410","article-title":"Renal tubular function in patients with beta\u2010thalassaemia major in Zahedan, southeast Iran","volume":"49","author":"Sadeghi\u2010Bojd S.","year":"2008","journal-title":"Singapore Medical Journal"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2011.03.018"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccx.0000184300.68383.95"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06455.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08720.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23569"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1465-7"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13217","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.13217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:33:40Z","timestamp":1696347220000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,17]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/bjh.13217"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13217","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2014,11,17]]},"assertion":[{"value":"2014-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}